Dana-Farber News· @DanaFarberNews · X·· 1 天前评分70
正文 · 机器翻译
#BreastCancer 研究在 #ESMO26：@DanaFarber 的 Antonio Gioradano 医学博士介绍了 atirmociclib + fulvestrant 用于既往 CDK4/6 抑制剂治疗后出现进展的 HR+/HER2- 晚期乳腺癌的疗效和安全性——来自 2 期 FOURLIGHT-1 研究的数据。
22 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Dana-Farber News · x.com